Pharmaceutical price comparisons across the European Union and relative affordability in Cyprus by Petrou, Panagiotis & Vandoros, Sotiris
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
King’s Research Portal 
 
DOI:
10.1016/j.hlpt.2016.07.009
Document Version
Peer reviewed version
Link to publication record in King's Research Portal
Citation for published version (APA):
Petrou, P., & Vandoros, S. (2016). Pharmaceutical price comparisons across the European Union and relative
affordability in Cyprus. Health Policy and Technology, 5(4), 350-356. DOI: 10.1016/j.hlpt.2016.07.009
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 06. Nov. 2017
Author’s Accepted Manuscript
Pharmaceutical price comparisons across the
European Union and relative affordability in
Cyprus
Panagiotis Petrou, Sotiris Vandoros
PII: S2211-8837(16)30059-4
DOI: http://dx.doi.org/10.1016/j.hlpt.2016.07.009
Reference: HLPT198
To appear in: Health Policy and Technology
Received date: 19 April 2016
Revised date: 21 July 2016
Accepted date: 30 July 2016
Cite this article as: Panagiotis Petrou and Sotiris Vandoros, Pharmaceutical price
comparisons across the European Union and relative affordability in Cyprus,
Health Policy and Technology, http://dx.doi.org/10.1016/j.hlpt.2016.07.009
This is a PDF file of an unedited manuscript that has been accepted for
publication. As a service to our customers we are providing this early version of
the manuscript. The manuscript will undergo copyediting, typesetting, and
review of the resulting galley proof before it is published in its final citable form.
Please note that during the production process errors may be discovered which
could affect the content, and all legal disclaimers that apply to the journal pertain.
www.elsevier.com/locate/hlpt
 1 
Pharmaceutical price comparisons across the European 
Union and relative affordability in Cyprus 
 
 
Panagiotis Petroua and Sotiris Vandorosb,c 
 
a Cyprus Health Insurance Organisation and Open University, Cyprus 
b King’s College London, London, UK 
c London School of Economics and Political Science, London, UK  
 
 
Abstract 
 
This paper performs price comparisons of branded pharmaceutical products in 
markets of eleven European Union countries. We follow a Laspeyres index 
approach, using Cyprus as the base country and analyse prices in the private and 
public markets and also consider biotechnology products separately. We find 
that Germany, Denmark and Austria demonstrate the highest pharmaceutical 
prices in the EU, followed by Cyprus. When adjusting for per capita income, 
Cyprus demonstrates the highest prices. Given that there is no universal health 
insurance in Cyprus, and that the country is facing a financial crisis, our findings 
underline possible affordability problems for patients. In order to remove 
barriers to access to medicines, pharmaceutical pricing regulation could be 
adjusted and price revisions should take place more frequently, and, most 
importantly, Cyprus must move in the direction of adopting universal health 
insurance.  
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1. Introduction  
Although the EU is a single market, different pharmaceutical pricing 
regulation applies across EU countries, leading to price differences. These 
differences have been studied in the past [1-6], but given the dynamic nature of 
prices, exchange rates and regulation, this topic merits a regular update. Most 
previous studies focused on the largest five EU markets, and, therefore, a country 
that has not been included in previous price comparisons and whose 
pharmaceutical market demonstrates peculiarities is Cyprus. Cyprus is a small 
market, and total pharmaceutical expenditure was 211 million Euros in 2011[7]. 
The rate of increase of pharmaceutical expenditure outpaces the increase in any 
other health related expenditure; in 2011 pharmaceutical expenditure increased 
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by 4.83% [8], while the economy grew at the rate of 0.5 %.  In 2011, Cyprus 
submerged in a financial crisis and its pharmaceutical market shrunk as an 
aftermath of the austerity policies and memorandum-impelled reforms. 
Indicatively in 2013 total pharmaceutical expenditure was constrained to 198.4 
million euro, attributed primarily to the reduction of public expenditure[9]. 
 Most EU countries have universal health insurance, meaning that the 
entire population is covered for healthcare, including pharmaceuticals (subject 
to co-payments and other restrictions). In Cyprus, however, public health 
insurance does not apply to the entire population. Only public sector employees, 
families with an annual income below a certain threshold (about 15,000 Euros 
per year) and patients suffering from particular chronic diseases are covered by 
public health insurance. Therefore, it does not come under surprise that private 
pharmaceutical expenditure in Cyprus exceeds public expenditure (106.8 vs 104 
million euros), a unique feature among EU countries. Notably, private 
pharmaceutical expenditure does not include co-payments applicable in the 
public health care sector, which is estimated to be around 5-6 million euros per 
year. 
Prior to 2004, Cyprus maximum public retail prices (PRP) were based on 
the ex-factory price of the origin country. This lacked any clear rationale and 
clearly created incentives for marketing authorisation holder (MAH) to supply 
products from expensive countries in order to maximize their profit margins, 
due to the proportionate system that was implemented. As a result Cyprus had 
considerably high prices, even compared to expensive countries such as Sweden 
and Denmark [10]. In 2005 a major reform took place and a new external price 
referencing scheme policy, which is very popular across the EU, was introduced. 
The reference price in Cyprus is determined as the average of available prices in 
Austria, France, Greece and Sweden, plus a 3 percent markup to cover importing 
costs and a 37 percent pharmacist mark-up fee. The rationale behind the choice 
of reference countries was to include one expensive, one cheap and two medium-
price countries, in order to reflect an average EU price. Five alternative countries 
were also determined as alternatives when a product is not present in one or 
more of the reference countries (Denmark, Germany (high price), Italy, Belgium 
(average price), Spain, Portugal (low price)[10]. However, price revisions have 
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not taken place in five years (2005-2009), while prices have decreased 
elsewhere in the EU [11-12]. Moreover, composition and classification of 
countries in the basket –regarding their price level status – has not been updated 
and the classification of the basket countries as expensive, medium and cheap 
was passively carried over, based on 2005 data.  The fact that prices have not 
been updated in such a long period (as opposed to every 1-24 months in other 
countries) provides a rationale for comparing prices in Cyprus with prices in 
other EU countries, and for studying the affordability of drugs in this country. 
This is further substantiated by the fact that the basket of countries and price 
calculations have not been revised since the introduction of this pricing scheme. 
Previous studies on cross-country pharmaceutical price comparisons 
have shown interesting results. Kanavos et al 2013 compared prices across large 
global markets and their findings revealed that higher prices in the US may be 
attributed to earlier uptake of new, expensive products [1]. Kanavos and 
Vandoros [2] compared prices across OECD countries using own-country 
weights (an approach commonly known as employing a Paasche price index), 
while Danzon and Chao (2000) used both Laspeyres and Paasche indexes to 
show how prices differed across the largest markets globally in the nineties [6]. 
Danzon and Furukawa, in 2003 and 2008, provided newer evidence on cross-
country price comparisons [5-6]. Finally, it has been shown that income does not 
have a consistent impact on prices, as those of developing countries often 
exceeded prices in high-income countries [3].  
There are many methodological issues surrounding cross-country price 
comparisons [13]. Prices can be recorded at different levels. For example, one 
can distinguish between wholesaler and retail prices, and may select a sample of 
originator or generic products. In addition, when comparing prices, the choice of 
weights for the prices included in the index is of great importance.  
Previous studies have focused on comparisons between the US and other 
large global markets, usually including only the five largest EU markets. 
Therefore, price differences between EU countries remain largely unexplored. In 
addition, exchange rate fluctuations and changes in price regulation, especially 
following the recent financial crisis, have led to significant changes in relative 
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prices, thus generating the need for an update on cross-country price 
comparisons.  
 This study addresses an important issue of price comparisons from the 
point of view of a small EU market (Cyprus). However, it has great policy 
relevance for all EU countries and advances the literature by (a) comparing 
prices across many EU countries, as opposed to previous studies that largely 
focused their attention on the largest five markets; (b) providing an update on 
cross-country price comparisons; (c) considering affordability, as we take per 
capita income into account; (d) studying both private and public segments of the 
market; and (e) presenting a separate index for biotechnology products.   
 
3. Data and Methods  
3.1 Data  
For the purpose of the study we used pricing data on 100 drugs from 
eleven EU countries in 2011. The initial sample of products chosen were the 100 
top-selling prescription only products (formulations/strengths) in the private 
market in Cyprus, which accounted for about 35 percent of the Cypriot market. 
In order to ensure a common sample across countries, we excluded 46 products 
that were not present in all countries, and to avoid restricting the drug sample 
further, we did not include some countries (Finland, Portugal, Belgium, Poland, 
Latvia, Slovakia and Czech Republic). The final sample includes 54 products in 
the private market in eleven countries (Austria, Cyprus, Denmark, France, 
Germany, Greece, Italy, Norway, Spain, Sweden and the United Kingdom), which 
account roughly for 20 percent of total market value. The sample consists of 51 
active ingredients –three of them were included in two different strengths.  All 
prices are provided at the retail (pharmacy) level, which is relevant from a policy 
and affordability perspective. Furthermore, ex-factory prices are not officially set 
in Cyprus. Based on wholesale prices, calculations could lead to an estimated but 
not actual price. There are several other reasons that justify preferring the retail 
price over the manufacturer or wholesale price (transparency, data availability, 
final price paid by patient or insurer) [14]. Moreover, several countries apply 
clawbacks and rebates on pharmacist margin, and pharmacist profit margins in 
Cyprus are close to the EU average.  
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Data for prices in each country were obtained from the health authorities’ 
official drug lists in each country (data sources are provided in the appendix). In 
case of discrepancies, we contacted the local authorities directly to cross-check 
our data. For countries that are not part of the Euro zone (UK and Sweden), 
prices were converted into Euros based on the annual average exchange rate for 
2011[15]. In order to standardise packaging disparities we used the price per 
defined daily dose (DDD) in order to ensure comparability across countries in 
case packages differed. DDD “is the assumed average maintenance dose per day 
for a drug used for its main indication in adults” as defined by the World Health 
Organization[16]. Since private sales data were not publicly available, sales in 
Cyprus were assessed based on market research in 15 high-volume pharmacies 
and interviews with twelve key opinion leaders. We did not observe any 
significant deviations, meaning that the market shares we used are reliable.    
 All products included in the study are originators, as the purpose of the 
paper is to perform cross-country originator price comparisons, due to the fact 
that in the presence of patent protection there are no cheap generic alternatives 
available. Furthermore, while there are many policy tools available for 
authorities to regulate prices in generic markets, this is not the case in on-patent 
markets.  
In our study we also assess the prices of products procured by the public 
health care sector. Sales data for the public health care sector were obtained 
from the Ministry of Health, based on which we derived market shares, in order 
to weigh each product accordingly in the price index. We selected the top 50 
products of the public market in value, which correspond to 35% of the total 
market value. Based on availability in the other countries, we ended up with a 
common sample of 22 products in the public market, whose value corresponds 
to 20% of public health care value[17]. This will serve as a proxy since discounts 
often apply to the price that public health insurance pays. Discounts are usually 
undisclosed and not reflected in the final price in the public segment of the 
market. As such, these discounts cannot be captured in the price index [18-19]. 
In Cyprus in particular, the procurement of drugs in the public market is done via 
tenders, often leading to lower prices than the list price; but significant cuts 
occur mainly in generic markets rather than originator ones, where there are no 
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direct competitors[20]. Not being able to capture discounts and tenders is a 
limitation of the study. However, such discounts do not apply in the private 
market, so price comparisons on this market segment are not affected by this 
limitation. 
 
3.2 Methods  
Previous work has provided the foundations for a clear and robust 
methodological approach to cross-country pharmaceutical price comparisons, 
that we follow in this paper [1-2, 4-6]. We follow a Laspeyres price index 
approach, according to which the product weights of a single country (the base 
country) apply to all countries. Therefore, the Laspeyres index compares prices 
as if all countries demonstrated the same product market shares. The Laspeyres 
Index is calculated as follows:  
 
 
PL 
p jiq j 0
j1
n

p j0q j 0
j1
n

100   (1) 
 
where pji is price of product j in country i,  pj0 is price of product j in the base 
country, and qj0 is quantity of product j in the base country, for a sample of n 
products.  
For the purpose of this study, this approach is preferred to the Paasche 
index, in which case each country has its own weights, and as such would be a 
better way of comparing expenditure rather than simply prices. When using the 
Paasche index, two countries that theoretically have the same prices may 
demonstrate differences in the Paasche index, if in one country more expensive 
products have a higher market share than in the other, thus reflecting different 
consumption patterns. Both indexes have are useful, but in this study we use the 
Laspeyres index with Cyprus as base country because (a) the study is conducted 
from a Cyprus perspective, especially as the private market is vital in Cyprus and 
less important in other countries due to differences in public health insurance 
coverage; and (b) we were able to calculate weights for the Cyprus market as we 
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had access to sales data, which we did not have for other countries.  We also 
performed the same analysis for the same sample, excluding VAT from the 
prices, due to significant variation among EU countries [21]. The purpose of VAT 
is to fund the government budget, so its importance is restricted to non-
healthcare aspects.   
In addition to the primary objective of the study, we also performed price 
comparisons for biotechnology products (anti-TNF, TKIs VEGF inhibitors) due to 
their high prices and value increase rate 1. Finally, we also adjusted price indexes 
for per capita GDP PPP, in order to measure affordability, as this highlights the 
financial burden on individuals via contributions or taxes, in the case of public 
spending, or out-of-pocket payments, in the case of private spending [22].  
With the exception of the United Kingdom, Denmark, Sweden and 
Germany, all other countries included in the analysis use external reference 
pricing to set originator prices[23]. The UK employs profit controls (as part of 
the Pharmaceutical Price Regulation Scheme) [24] and Germany has free pricing 
[25]. In Sweden, prices are submitted by the marketing authorization holder to 
the competent authorities and are either rejected or accepted (but not 
negotiated) based on the cost-effectiveness principle, the human value principle 
and the need and solidarity principle [26]. Denmark applies free pricing although 
some restrictions apply at the reimbursement level [27].  
 
4. Results  
The price indexes of the private sector are presented in Table 1. These 
prices reflect out-of-pocket payment since all expenses burden the patient, 
unless they are covered by an optional private insurance. For countries with 
universal health insurance, this is not one of the most important issues in 
healthcare. However, due to the lack of universal health insurance in Cyprus, a 
significant part of the population relies on the private market, meaning that this 
is crucial for access to medicines. In the private sector, Germany, Denmark, 
                                                          
1 One fast growing segment and a cause for serious concerns is the one of low volume high value 
biotechnology medicines. This section is characterized by oligopoly and lack of generics. 
Indicatively, in Germany, the turnover of the Top 10 indications according to ATC-3 show that the 
highest increase (as compared to the previous year) occurs in the areas of “other antineoplastic 
agents” (annual increase of 33.15 percent and anti-TNF preparations (25,8 percent increase) 
[28]. 
 8 
Austria, are the three most expensive countries, followed by Cyprus. The 
countries with the lowest prices are France and Greece (Table 1). When 
adjusting for GDP per capita, the highest prices are found in Cyprus, followed by 
Germany and Denmark. The countries with the lowest relative prices are the UK, 
France and Norway.  
We performed the same analysis for the same price cohort without VAT. 
Germany is still the country with the highest prices, followed by Austria. Cyprus 
is third, and Greece is last in the sample. After adjusting for GDP PPP Cyprus 
demonstrates the highest prices, followed by Germany, while Norway and UK 
have the lowest prices (Table 2)   
 
[Insert Table 1 here] 
[Insert Table 2 here] 
 
Table 3 presents the price indexes of biotechnology drugs. The highest 
prices are identified in Germany, with Cyprus ranking second and Italy third. 
France, Greece and the UK are in the last positions among the eleven countries of 
the sample. When adjusting for GDP per capita, Cyprus ranks first, followed by 
Germany and Italy. In this case, Sweden, UK and Norway have the lowest relative 
prices.  
The price indexes for the public market are presented in Table 4. 
Germany demonstrates the highest prices, followed by Denmark and Austria, 
while Cyprus ranks fourth. The lowest prices in the public market are 
demonstrated in France (30.08 percent lower than Cyprus), Greece (35.10 
percent lower than Cyprus) and the UK (40.80 percent lower than Cyprus). 
When adjusting for GDP PPP, Cyprus ranks first, followed by Italy, Germany and 
Denmark. France, UK and Norway rank in the three lowest places in the sample.  
 
[Insert Table 3 here] 
[Insert Table 4 here] 
 
5. Discussion and Conclusions  
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 We have used a Laspeyres index to compare pharmaceutical prices 
across eleven EU countries.  This study provides insight into a topic that has been 
mostly limited to the EU G5 (France, Germany, Italy, Spain, UK) and North 
America in previous studies. Our results show that Germany and Denmark 
demonstrate the highest private market prices and Cyprus ranks third.  When 
adjusting for income, Cyprus is the highest-priced country in the private market, 
in which Greece ranks last. Cyprus also demonstrates the second highest prices 
in biotechnology markets and ranks first when adjusting for income. Results for 
the public sector are in line with the corresponding findings for the private 
sector, which conveys more clearly the situation in Cyprus (but they should be 
interpreted with caution). This verifies our findings, indicating that Germany, 
Denmark and Cyprus are among the most expensive markets, while when 
adjusting for affordability Cyprus is in the first place, followed by Germany, while 
UK, France and Norway demonstrate the best affordability rates.  
Currently, pricing is the single supply-side measure applicable in the 
private health care sector in Cyprus, which is void of other measures frequently 
utilised by EU countries such as generic substitution, guidelines, monitoring and 
auditing[29], which underlines the importance of acting on pricing. Furthermore, 
the current financial situation in Cyprus means that high prices may create 
affordability problems, leading to barriers to access to medicines, a pattern 
already observed in other recession countries [30]. In the context of pricing 
policies, several authors correlate income level with prices. [10, 31, 32] and 
previous studies found a strong positive correlation of GDP PPP with 
pharmaceutical prices in EU countries [22]. As a result, by adjusting prices by 
per-capita GDP we can extract a better picture with regards to comparative 
affordability.  
The fragmentation of the Cypriot pharmaceutical market into public and 
private sectors creates a heterogeneous environment which impedes the 
introduction and dissemination of new policies. Private pharmaceutical 
expenditure does not relate to financial deficit and burdens individuals, and, 
consequently, the Cypriot government does not have a strong fiscal motive to 
pursue price reductions in the private sector. This underlines the need for the 
adoption of a National Health System [33]. Pricing revisions should be performed 
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in the context of health reforms and transition towards a new healthcare system. 
Designation of one single payer, in the form of the much-anticipated National 
Health System will enable a straightforward intervention to prices and will 
address affordability issues [34].   
Currently, the Cypriot health authorities may want to consider seeking 
alternative ways of pricing drugs, or to perform price revisions more frequently, 
so that prices can reflect the current situation in the reference countries, 
especially given the price cuts in many EU countries. Moreover, given the rapid 
deterioration of its fiscal position, Cyprus should also consider a new basket of 
countries, based on new data. Alternatively, Cyprus could consider a different 
formula for price estimations, and price weights could be higher for countries 
with the same fiscal adversities, such as Spain and Greece.  Current data provide 
an exemplary framework for reassessment of countries, based on price level, 
which would lead to realignment of classification of referencing countries. In this 
context, classification of countries as expensive, medium and cheap should be 
more accurate and final prices should depict more clearly the prices in the 
country of origin.   
 In any case, it is worth mentioning that prices include the manufacturer 
price, the wholesaler and pharmacist mark-ups, and, in some countries, VAT 
[1,2,4,5,6]. Therefore, price differences may not reflect solely higher 
manufacturer prices (at which level regulation usually applies), but also 
differences in mark-ups and indirect taxes.  
Due to the size and location of Cypriot pharmaceutical market, a balance 
must be kept, in order to avoid any threats to continuous and undisrupted supply 
to the local market, as very low prices may make the market unattractive and 
may finally lead to shortages. Moreover, very low prices would significantly 
delay launch of new products in Cyprus, since this would prevent a spill-over 
effect of its low prices to more significant and bigger markets via external 
reference pricing.  The small size of the market also implies that due to 
economies of scale issues, dedicated departments for complex pricing methods 
cannot operate, leading to the adoption of external reference pricing despite the 
fact that this policy has been criticised as overly simplistic and lacking any 
theoretical background [35-36].  
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We performed a separate analysis for biotechnology products, which 
includes some highly individualised products with a high annual growth rate, 
that exerts significant pressure on pharmaceutical expenditure. Due to their 
complexity level, interchangeability between these agents is complicated, which 
shifts bargaining power to their side and render other reimbursement 
approaches rather inefficient. Alarmingly, Cyprus has high prices in this sector, 
and the highest after GDP PPP per capita adjustement. This is further aggravated 
by the fact that after patent expiry, these products are subject to biosimilars 
rather than generics. Biosimilars are subject to a different regulatory framework, 
which ultimately leads to smaller savings, compared to the steep price 
reductions reported in generic medicines’ procurement [20].  
            This study is not without limitations. While using the Laspeyres index is 
perfectly relevant for Cyprus and also gives a picture of prices in other EU 
countries, any findings for these countries must be treated with caution, due to 
the fact that weights reflect consumption patterns in Cyprus. Most importantly, 
the list prices used in the public sector price index do not include any discounts, 
rebates and clawbacks or any cuts achieved via tendering or managed entry 
agreements.  Moreover, despite our initial study design provided a sample of 
35% of Cyprus market, we ended up with a lower sample, as a trade-off to 
safeguard a common basket of products across sample countries, which would 
render our findings reliable. Finally, the use of DDD, despite being a rational 
approach endorsed by the WHO, does not take into consideration any differences 
in package size.  
Cross-country price comparisons among EU countries are important for 
policy makers, and future research can provide updates after any changes in 
regulation, and can also study this issue using weights of different markets.  
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TABLES  
 
Table 1. Laspeyres price index, private market 
Countries Index Index adjusted by GDP PPP 
Germany 127.54 97.85 
Denmark 120.40 94.22 
Austria  110.61 76.89 
Cyprus 100.00 100.00 
Sweden 93.11 67.02 
Norway 92.62 50.36 
Italy 96.05 91.66 
UK 69.65 56.11 
Spain 74.10 70.35 
France  72.14 59.66 
Greece 66.89 73.96 
 
 
 
Table 2. Laspeyres price index, private market excluding VAT 
Countries Index Index adjusted by GDP PPP 
Germany 108.68 83.38 
Austria 104.32 72.52 
Cyprus 100.00 100.00 
Sweden  97.85 70.42 
Denmark 94.83 74.21 
Italy 90.99 86.83 
Spain 74.69 70.90 
France  74.10 61.28 
UK 73.22 58.90 
Norway 72.86 39.61 
Greece   65.83 72.78 
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Table 3. Laspeyres price index, biotechnology products 
Countries Index Index adjusted by GDP PPP 
Germany 104.91 80.48 
Cyprus 100.00 100.00 
Italy 99.63 95.08 
Austria 96.30 66.94 
Denmark 96.01 75.15 
Norway 80.50 43.77 
Sweden 73.51 53.90 
Spain 71.57 67.95 
France 69.55 57.20 
Greece  64.75 71.06 
United Kingdom 58.35 47.00 
 
 
 
Table 4. Laspeyres price index, public market 
Countries  Index Index adjusted by GDP PPP 
Germany 114.83 88.10 
Denmark 105.75 82.76 
Austria 101.35 70.30 
Cyprus 100.00 100.00 
Italy 99.33 94.80 
Norway 81.98 44.57 
Sweden 80.67 58.06 
Spain 70.49 66.92 
France 69.02 57.08 
Greece 64.90 71.76 
United Kingdom 59.20 47.69 
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APPENDIX  
 
Table A1. Price Sources   
 
Austria Common European Drug Database 
(CEDD) 
http://cedd.oep.hu/ 
Belgium Common European Drug Database 
(CEDD) 
http://cedd.oep.hu/ 
Czech 
Republic 
Common European Drug Database 
(CEDD) 
http://cedd.oep.hu/ 
Cyprus Pharmaceutical services MoH http://www.moh.gov.cy/
moh/phs/phs.nsf/dmlpri
celist_en/dmlpricelist_en
?OpenDocument 
Denmark Medicin Priser  http://www.medicinprise
r.dk/ 
Finland Common European Drug Database 
(CEDD) 
http://cedd.oep.hu  
France Ministry of Health http://medicprix.sante.g
ouv.fr/welcome.do 
Germany  DIMDI http://www.dimdi.de/sta
tic/en/amg/fbag/index.h
tm 
Greece Ministry of Health http://www.yyka.gov.gr
/articles/times-
farmakwn/deltia-timwn 
Latvia Common European Drug Database 
(CEDD) 
http://cedd.oep.hu/ 
Italy L'Agenzia Italiana del farmaco (AIFA) http://farmaco.agenziaf
armaco.it/index.php 
Norway Statens legemiddelverket http://www.legemiddelv
erket.no/templates/Inter
Page____38824.aspx?fil
terB... 
Poland Common European Drug Database 
(CEDD) 
http://cedd.oep.hu  
Portugal Infarmed  http://www.infarmed.pt/
infomed/inicio.php 
Slovakia Common European Drug Database 
(CEDD) 
http://cedd.oep.hu  
Spain Vademecum http://www.vademecum
.es/ 
Sweden The Dental and Pharmaceutical Benefits 
Agency (TLV) 
http://www.tlv.se/in-
english/ 
United 
Kingdom 
British National Formulary; http://bnf.org/bnf/index
.htm 
National Health Service Drug Tariff for 
England and Wales 
http://www.ppa.org.uk/
ppa/edt_intro.htm  
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Highlights  
 
We compare pharmaceutical prices in 11 EU countries, using Cyprus as a base country 
 
We derive indexes for the private and public markets and are also adjusted for income 
 
We find that Cyprus demonstrates one of the highest prices in the sample  
 
Other countries with high prices include Germany, Denmark and Austria  
 
Results from the private market highlight the need for universal health insurance in Cyprus  
 
